Zoekresultaten - Christiane Smerling

  • Toon 1 - 5 resultaten van 5
Verfijn jouw resultaten
  1. 1
    <sup>177</sup>Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results

    <sup>177</sup>Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results door Richard P. Baum, Aviral Singh, Christiane Schuchardt, Harshad Kulkarni, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke, Christiane Smerling

    Gepubliceerd in 2017
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    N-Terminal Modifications Improve the Receptor Affinity and Pharmacokinetics of Radiolabeled Peptidic Gastrin-Releasing Peptide Receptor Antagonists: Examples of <sup>68</sup>Ga- and <sup>64</sup>Cu-Labeled Peptides for PET Imaging

    N-Terminal Modifications Improve the Receptor Affinity and Pharmacokinetics of Radiolabeled Peptidic Gastrin-Releasing Peptide Receptor Antagonists: Examples of <sup>68</sup>Ga- an... door Eleni Gourni, Rosalba Mansi, Mazen Jamous, Beatrice Waser, Christiane Smerling, Antje Burian, Franz Buchegger, Jean Claude Reubi, Helmut R. Maëcke

    Gepubliceerd in 2014
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Proof of Therapeutic Efficacy of a <sup>177</sup>Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model

    Proof of Therapeutic Efficacy of a <sup>177</sup>Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model door Jörg Schulz, Martin Rohracker, Marvin Stiebler, Jürgen Goldschmidt, Franziska Stöber, Mercedes Noriega, A. Pethe, Mathias Lukas, Frank Osterkamp, Ulrich Reineke, Aileen Höhne, Christiane Smerling, Holger Amthauer

    Gepubliceerd in 2017
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans Results

    Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans Results door Richard P. Baum, Christiane Schuchardt, Aviral Singh, Maythinee Chantadisai, F Robiller, Jingjing Zhang, Dirk Müeller, Alexander Eismant, Frankis Almaguel, Dirk Zboralski, Frank Osterkamp, Aileen Hoehne, Ulrich Reineke, Christiane Smerling, Harshad Kulkarni

    Gepubliceerd in 2021
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

    Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy door Dirk Zboralski, Aileen Hoehne, Anne Bredenbeck, Anne Schumann, Minh Nguyen, Eberhard Schneider, Jan Ungewiss, Matthias Paschke, Christian Haase, Jan L. von Hacht, Tanya T. Kwan, Kevin Lin, Jan Lenore, Thomas C. Harding, Jim Xiao, Andrew D. Simmons, Ajay-Mohan Mohan, Nicola Beindorff, Ulrich Reineke, Christiane Smerling, Frank Osterkamp

    Gepubliceerd in 2022
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: